Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mercaptopurine Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | PI4KA | P42356 | 2/20 | 0.55 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.55 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.55 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | G6PD | P11413 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | MARK3 | P27448 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mercaptopurine Anhydrous SCHEMBL29684795 | 0.98 | LMNA (0.57) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL8844 | 0.98 | LMNA (0.57) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL31379732 | 0.96 | LMNA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL5144254 | 0.96 | LMNA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL30834915 | 0.96 | LMNA (0.55) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL28474534 | 0.87 | HSD17B10 (0.50) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL1820743 | 0.82 | PI4KA (0.43) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL4447615 | 0.81 | MKNK1 (0.47) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| Mercaptopurine Anhydrous SCHEMBL5534039 | 0.80 | ALDH1A1 (0.44) | LMNAPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL29559610 | 0.76 | LMNA (0.57) | LMNAPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115705-A1 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-04-11 | — | — | US | claimed |
| CN-117295505-A | Modulation of the milk philin subfamily 3 member A1 (BTN 3A1, CD 277) | 加利福尼亚大学董事会 | 2023-12-26 | — | — | CN | claimed |
| EP-4288074-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | The Regents of The University of California Santa Cruz (US) | 2023-12-13 | — | — | EP | claimed |
| WO-2022170344-A1 | REGULATION OF BUTVROPHILIN SUBFAMILY 3 MEMBER A1 (BTN3A1, CD277) | MARSON ALEXANDER (US) | 2022-08-11 | — | — | WO | claimed |
| US-20140294972-A1 | Oral Suspension | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2014-10-02 | — | — | US | claimed |
| US-8765712-B2 | Agent for preventing and treating pityriasis versicolor | JUSTUS-LIEBIG-UNIVERSITAET GIESSEN (DE) | 2014-07-01 | — | — | US | claimed |
| WO-2013034931-A1 | ORAL SUSPENSION | NOVA BIO-PHARMA TECHNOLOGIES LIMITED (GB) | 2013-03-14 | — | — | WO | claimed |
| US-20120129800-A1 | Agent For Preventing And Treating Pityriasis Versicolor | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2012-05-24 | — | — | US | claimed |
| EP-2387396-A1 | AGENT FOR PREVENTING AND TREATING PITYRIASIS VERSICOLOR | Justus-Liebig-Universität Gießen (DE) | 2011-11-23 | — | — | EP | claimed |
| US-8041481-B2 | Power steering system and method of influencing the damping of a power steering system | TRW AUTOMOTIVE GMBH (DE) | 2011-10-18 | — | — | US | claimed |
| WO-2009016379-A2 | NR4A AGONISTS ( 6-MERCAPTOPURINE) FOR INHIBITION OF NON-OCULAR SCARRING | RENOVO LIMITED (GB) | 2009-02-05 | — | — | WO | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| US-5854231-A | Pharmaceutical composition for inhibiting the growth of cancers | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-29 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-5043237-A | Inhibitor-containing photohardenable electrostatic master compositions having improved resolution | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-08-27 | — | — | US | claimed |
| EP-0436948-A2 | Inhibitor-containing photohardenable compositions having improved resolution | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1991-07-17 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115705-A1 | Regulation of Butyrophilin subfamily 3 member A1 (BTN3A1, CD277) | BTN3A1, BTF3, CD274 | LMNA 3125/4885PI4KA 3505/4885PI4K2B 3576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.